317335-15-2

Basic information

• Product Name: 2-Pyridinecarboxylicacid,4-(hydroxymethyl)-,methylester(9CI)
• Synonyms: 4-(hydroxymethyl)-2-Pyridinecarboxylic acid methyl ester;2-Pyridinecarboxylicacid,4-(hydroxymethyl)-,methylester(9CI);4-Hydroxymethyl-pyridine-2-carboxylic acid methyl ester;Methyl 4-(hydroxymethyl)pyridi;Methyl 4-(hydroxymethyl)pyridine-2-carboxylate, 95%;Methyl 4-(hydroxyMethyl)picolinate
• CAS NO: 317335-15-2
• Molecular Formula: C₈H₉NO₃
• Molecular Weight: 167.16
• Product Categories: GLYCINESCAFFOLD
• Mol File: 317335-15-2.mol
• Article Data: 3

Chemical Properties

• Melting Point: 74-76℃
• Boiling Point: 335.8°C at 760 mmHg
• Flash Point: 156.9°C
• Appearance: /
• Density: 1.244g/cm³
• Vapor Pressure: 4.61E-05mmHg at 25°C
• Refractive Index: 1.546
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 13.17±0.10(Predicted)
• CAS DataBase Reference: 2-Pyridinecarboxylicacid,4-(hydroxymethyl)-,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarboxylicacid,4-(hydroxymethyl)-,methylester(9CI)(317335-15-2)
• EPA Substance Registry System: 2-Pyridinecarboxylicacid,4-(hydroxymethyl)-,methylester(9CI)(317335-15-2)

Safety Data

• Hazardous Substances Data: 317335-15-2(Hazardous Substances Data)

Usage

Description

2-Pyridinecarboxylic acid, 4-(hydroxymethyl)-, methyl ester (9CI), also known as Methyl 4-(hydroxymethyl)pyridine-2, is an organic compound derived from pyridine. It features a pyridine ring with a carboxylic acid group at the 2nd position, a hydroxymethyl group at the 4th position, and a methyl ester group. 2-Pyridinecarboxylicacid,4-(hydroxymethyl)-,methylester(9CI) is characterized by its potential reactivity and versatility in chemical synthesis.

Uses

Used in Pharmaceutical Industry:
2-Pyridinecarboxylic acid, 4-(hydroxymethyl)-, methyl ester (9CI) is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a key component in the development of new drugs, particularly those targeting the central nervous system or other biologically active molecules.
Used in Chemical Research:
In addition to its applications in the pharmaceutical industry, 2-Pyridinecarboxylic acid, 4-(hydroxymethyl)-, methyl ester (9CI) also finds use in chemical research. It serves as a valuable building block for the synthesis of more complex organic molecules, contributing to the advancement of chemical knowledge and the development of novel materials and compounds.

InChI:InChI=1/C8H9NO3/c1-12-8(11)7-4-6(5-10)2-3-9-7/h2-4,10H,5H2,1H3

Upstream product

• 117423-42-4 4-<<(tert-butyldimethylsilyl)oxy>methyl>pyridine N-oxide 
• 117423-41-3 4-((tert-butyldimethylsilyloxy)methyl)pyridine 
• 586-95-8 pyridine-4-methanol 
• 67-56-1 methanol 
• 923169-37-3 4-(hydroxymethyl)pyridine-2-carboxylic acid 
• 117423-43-5 2-cyano-4-[{(tert-butyldimethylsilyl)oxy}methyl]pyridine 

Downstream Products

• 64463-46-3 methyl 4-formylpicolinate 

Relevant articles and documents

Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3

Both cholinesterases (AChE and BChE) and kinases, such as GSK-3α/β, are associated with the pathology of Alzheimer's disease. Two scaffolds, targeting AChE (tacrine) and GSK-3α/β (valmerin) simultaneously, were assembled, using copper(I)-catalysed azide alkyne cycloaddition (CuAAC), to generate a new series of multifunctional ligands. A series of eight multi-target directed ligands (MTDLs) was synthesized and evaluated in vitro and in cell cultures. Molecular docking studies, together with the crystal structures of three MTDL/TcAChE complexes, with three tacrine-valmerin hybrids allowed designing an appropriate linker containing a 1,2,3-triazole moiety whose incorporation preserved, and even increased, the original inhibitory potencies of the two selected pharmacophores toward the two targets. Most of the new derivatives exhibited nanomolar affinity for both targets, and the most potent compound of the series displayed inhibitory potencies of 9.5 nM for human acetylcholinesterase (hAChE) and 7 nM for GSK-3α/β. These novel dual MTDLs may serve as suitable leads for further development, since, in the micromolar range, they exhibited low cytotoxicity on a panel of representative human cell lines including the human neuroblastoma cell line SH-SY5Y. Moreover, these tacrine-valmerin hybrids displayed a good ability to penetrate the blood-brain barrier (BBB) without interacting with efflux pumps such as P-gp.

1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof

Certain 1-(aromatic- or heteroaromatic-substituted-3-(heteroaromatic substituted)-1,3-propanediones are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.